Article Versions Notes

Chiabotto G, Grignani G, Todorovic M, Martin V, Centomo ML, Prola E, Giordano G, Merlini A, Miglio U, Berrino E, et al. Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights. Cancers. 2020; 12(6):1519. https://doi.org/10.3390/cancers12061519

Chiabotto, Giulia, Giovanni Grignani, Maja Todorovic, Valentina Martin, Maria Laura Centomo, Elisa Prola, Giorgia Giordano, Alessandra Merlini, Umberto Miglio, Enrico Berrino, and et al. 2020. "Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights" Cancers 12, no. 6: 1519. https://doi.org/10.3390/cancers12061519

Chiabotto, G., Grignani, G., Todorovic, M., Martin, V., Centomo, M. L., Prola, E., Giordano, G., Merlini, A., Miglio, U., Berrino, E., Napione, L., Isella, C., Capozzi, F., Basiricò, M., Marsero, C., Gerardi, I., Venesio, T., Sangiolo, D., Aglietta, M., ... Pignochino, Y. (2020). Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights. Cancers, 12(6), 1519. https://doi.org/10.3390/cancers12061519